Frost & Sullivan

JANUARY 28, 2021

Global healthcare revenues in 2025 will exceed $2.6 28, 2021 – Frost & Sullivan’s recent analysis, Vision 2025—Rising Healthcare Expenditures and Disproportionate Improvement in Patient Outcomes Spur Disruptive Changes in the Global Healthcare Industry , forecasts that global healthcare revenues in 2025 will exceed $2.6

Biopharma 98

Biopharma Ecosystems Government 98

Frost & Sullivan

AUGUST 9, 2021

billion by 2025, at a CAGR of 29.8%, finds Frost & Sullivan. billion by 2025 from $1.23 Over the next two to three years, biopharma companies also will highly invest in DTx solutions, enabling the subsidized cost to patients in exchange for marketing and access to patient data. Santa Clara, Calif. –

Life science 98

Life science Biopharma Government Biopharmaceuticals 98

Frost & Sullivan

AUGUST 9, 2021

billion by 2025, at a CAGR of 29.8%, finds Frost & Sullivan. billion by 2025 from $1.23 Over the next two to three years, biopharma companies also will highly invest in DTx solutions, enabling the subsidized cost to patients in exchange for marketing and access to patient data. Santa Clara, Calif. –

Life science 90

Life science Biopharma Government Biopharmaceuticals 90

Frost & Sullivan

APRIL 3, 2024

Fuelling Growth: Strategic Investments, Acquisitions, and Expansions Samsung Biologics unveiled plans to expand capacity and geographic reach by initiating the construction of Bio Campus II with a $6 billion investment scheduled to begin operations in 2025 while completing its CGMP antibody-drug conjugate manufacturing facility within 2024.

Biopharmaceuticals 59

Biopharmaceuticals Biopharma Biotechnology Life science 59

Jake Jorgovan

FEBRUARY 5, 2025

Updated: February 2025 Biopharmaceutical consultants and consulting firms play a pivotal role in guiding companies through the intricate landscape of drug development, regulatory compliance, and market strategies. The Value of a Biopharma Consulting Firm Beyond mere compliance, these consultants offer strategic vision.

Biopharmaceuticals 130

Biopharmaceuticals Biopharma Biotech Life science 130

Jake Jorgovan

FEBRUARY 2, 2025

Updated: February 2025 "Science and everyday life cannot and should not be separated." - Rosalind Franklin It should go without saying, but life science can be quite complicated. Why work with Eradigm Consulting: Eradigm Consulting's approach is driven by a passion for high performance and delivering excellence in the biopharma industry.

Life science 130

Life science Biotech Biotechnology Engineering 130

Frost & Sullivan

APRIL 2, 2025

Held in New York during March 17-20, 2025, the event focused on pharmaceutical innovation, industry outlook, capacity expansion, and supply chain resilience, driven by the increasing digitization of drug development and manufacturing. trillion in 2024, is expected to grow at a 7% CAGR through 2030.

Biopharma 52

Biopharma Life science Contract research organization Strategic partnership 52